好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

PROSE: A Newly Developed Patient-Reported Outcome Scale for Encephalitis
Autoimmune Neurology
P3 - Poster Session 3 (12:00 PM-1:00 PM)
013

To develop a disease-specific outcome scale for autoimmune encephalitis (AIE).

AIE is a severe neurological disease, with long-lasting neurocognitive sequelae. Currently, generic clinical assessment scales are used to evaluate outcome, not capturing the depth of disease-specific sequelae, providing less power in clinical trials. Patient-Reported Outcome Measures (PROMs) assess outcomes most important to patients, ensuring clinical relevance in standard care and clinical trials. We developed a disease-specific Patient-Reported Outcome Scale for Encephalitis (PROSE).

Content validity of individual questions from previously applied PROMs was assessed (235 items) on relevance for the AIE population. We confirmed validity in several AIE focus groups, adding missing items based on key themes identified. AIE patients completed a questionnaire containing all items with content validity (170 items). We conducted a series of validation studies to achieve the most accurate assessment with the fewest items to evaluate levels of disease severity, including item and factor analysis, Rasch modelling and testing of reliability and convergent validity.

Self-reported data was collected for 206 patients with anti-NMDAR (n=87), anti-LGI1 (n=99) and anti-CASPR2 (n=20) encephalitis. Median time from disease onset was 3.5y (range 0-14y). Prospective, repeated assessments were available in 25 patients. Item, factor and Rasch analyses supported the viability of the 40-item PROSE as a unidimensional interval scale of disease severity. PROSE covers six domains assessing cognition, behavior, emotional and physical wellbeing, fatigue and activities of daily living (ADL). There was good overall model fit for the 40-item PROSE, with no evidence of misfitting items or persons (no fit residuals >1.5). Person separation reliability (Cronbach’s alpha 0.92) was acceptable, and total scores were reliable at re-test and in agreement with existing gold standards.

PROSE is a psychometrically robust, disease-specific patient-reported outcome assessment tool for autoimmune encephalitis.

Authors/Disclosures
Juliette Brenner, MD (Erasmus University Medical Center)
PRESENTER
Ms. Brenner has nothing to disclose.
Yvette Crijnen Yvette Crijnen has nothing to disclose.
Ilse Kulderij Ilse Kulderij has nothing to disclose.
Cinthia J. Ruhe Miss Ruhe has nothing to disclose.
Anke Tolido Anke Tolido has nothing to disclose.
Laura Kersten Laura Kersten has nothing to disclose.
Julia Verkoelen Julia Verkoelen has nothing to disclose.
Chelsey Kret Chelsey Kret has nothing to disclose.
Brigit Thomassen Brigit Thomassen has nothing to disclose.
Anna Bastiaansen Anna Bastiaansen has nothing to disclose.
Marienke de Brujin Marienke de Brujin has nothing to disclose.
Sammy Olijslagers Sammy Olijslagers has nothing to disclose.
Jeroen Kerstens, MD Mr. Kerstens has received research support from European Joint Programme on Rare Diseases. The institution of Mr. Kerstens has received research support from Erasmus Trust Fund.
Sharon Veenbergen Sharon Veenbergen has nothing to disclose.
Ava M. Easton, PhD (The Encephalitis Society) Dr. Easton has received personal compensation for serving as an employee of Encephalitis Society. Dr. Easton has received publishing royalties from a publication relating to health care.
Juna De Vries Juna De Vries has nothing to disclose.
Esther van den Berg, PhD Dr. van den Berg has nothing to disclose.
Peter Sillevis Smitt, MD (Erasmus MC) The institution of Dr. Sillevis Smitt has received research support from Euroimmun. Dr. Sillevis Smitt has received intellectual property interests from a discovery or technology relating to health care.
Melissa Mandarakas Melissa Mandarakas has nothing to disclose.
Maarten J. Titulaer, MD, PhD (Erasmus Medical Center) The institution of Dr. Titulaer has received research support from Dutch Epilepsy Foundations (NEF 19-08). The institution of Dr. Titulaer has received research support from CSL Behring. The institution of Dr. Titulaer has received research support from UCB. The institution of Dr. Titulaer has received research support from Netherlands Organisation for Scientific Research (ZonMW, Memorabel initiative and E-RARE UltraAIE) . The institution of Dr. Titulaer has received research support from Horizon Therapeutics / Amgen. The institution of Dr. Titulaer has received research support from Dioraphte (charity). The institution of Dr. Titulaer has received research support from Guidepoint Global LLC. The institution of Dr. Titulaer has received research support from ArgenX. Dr. Titulaer has received intellectual property interests from a discovery or technology relating to health care. Dr. Titulaer has received publishing royalties from a publication relating to health care.